- Home
- IMCR vs LOB Comparison
IMCR vs LOB Comparison
Compare IMCR & LOB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- LOB
- Stock Information
- Founded
- IMCR 2008
- LOB 2008
- Country
- IMCR United Kingdom
- LOB United States
- Employees
- IMCR N/A
- LOB N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- LOB Major Banks
- Sector
- IMCR Health Care
- LOB Finance
- Exchange
- IMCR Nasdaq
- LOB Nasdaq
- Market Cap
- IMCR 1.7B
- LOB 1.5B
- IPO Year
- IMCR 2021
- LOB 2015
- Fundamental
- Price
- IMCR $35.17
- LOB $33.95
- Analyst Decision
- IMCR Buy
- LOB Buy
- Analyst Count
- IMCR 10
- LOB 3
- Target Price
- IMCR $58.13
- LOB $42.33
- AVG Volume (30 Days)
- IMCR 250.5K
- LOB 271.5K
- Earning Date
- IMCR 08-07-2025
- LOB 07-23-2025
- Dividend Yield
- IMCR N/A
- LOB 0.37%
- EPS Growth
- IMCR N/A
- LOB N/A
- EPS
- IMCR N/A
- LOB 1.21
- Revenue
- IMCR $333,581,000.00
- LOB $406,003,000.00
- Revenue This Year
- IMCR $26.82
- LOB $41.81
- Revenue Next Year
- IMCR $8.15
- LOB $10.77
- P/E Ratio
- IMCR N/A
- LOB $26.82
- Revenue Growth
- IMCR 25.75
- LOB N/A
- 52 Week Low
- IMCR $23.15
- LOB $22.68
- 52 Week High
- IMCR $40.88
- LOB $50.57
- Technical
- Relative Strength Index (RSI)
- IMCR 53.52
- LOB 70.63
- Support Level
- IMCR $32.20
- LOB $31.82
- Resistance Level
- IMCR $37.63
- LOB $34.30
- Average True Range (ATR)
- IMCR 1.21
- LOB 1.00
- MACD
- IMCR 0.03
- LOB 0.02
- Stochastic Oscillator
- IMCR 53.90
- LOB 90.44
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About LOB Live Oak Bancshares Inc.
Live Oak Bancshares Inc operates as the bank holding company for the Live Oak Banking Company. The company specializes in lending and deposit-related services to small businesses nationwide. The company identifies and extends lending to credit-worthy borrowers both within specific industries, also called verticals, through expertise within those industries, and more broadly to select borrowers outside of those industries. A portion of the loans originated by the Bank are partially guaranteed by the Small Business Administration under the 7(a) Loan Program and the U.S. Department of Agriculture Rural Energy for America Program, Water and Environmental Program, Business and Industry and Community Facilities loan programs.